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Objectives: The purpose of this analysis was to estimate how higher persistence 
in RRMS patients treated with interferon beta 1-a and its electronic injection device 
(Rebismart®) affects the rate of escalation to 2nd line therapies. MethOds: A 2-year, 
decision-analytic model was developed to track a hypothetical cohort of 1,000 RRMS 
patients initiating treatment with either interferon beta 1-a and Rebismart® or 
another 1st line self-injectable disease modifying drug (DMD). The model calculated 
the expected probability of escalating to 2nd line therapy, which was defined as either 
Gilenya® or Tysabri®. Persistence curves were estimated from a real-world dataset 
collected from the UK NHS where at 2 years Rebismart® users had 83% persistence vs. 
60% in non- Rebismart® users. A market research study was utilized to determine the 
treatment pathways for non-persistent patients, where 39% transitioned to another 
1st line DMD; 21% abandoned therapy and 40% escalated to 2nd line therapies. One-
way sensitivity analyses (OWSAs) varied the probability of non-persistent 1st line 
patients escalating to 2nd line therapies from 5% to 100%. Results: The model esti-
mated that over two years 5.4% of patients on the Rebismart® device are expected to 
escalate to 2nd line therapy, while 18.3% of patients that initiated treatment on other 
DMDs are expected to escalate. At the lower bound of the OWSA, 0.68% of patients are 
expected to escalate on Rebismart®, vs. 2.3%; while at the upper bound of the OWSA, 
13.3% of Rebismart® patients are expected to escalate vs. 42.7%. cOnclusiOns: 
Higher persistence rates in RRMS patients initiating treatment with interferon beta 
1-a and the Rebismart® electronic device are expected to result in fewer escalations 
to 2nd line therapies relative to other self-injectable DMDs.
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Objectives: To assess the relative efficacy and safety of modified-release levodopa 
(IPX066), controlled-release levodopa and add-on therapy to immediate-release 
levodopa (including dopamine agonists, monoamine oxidase-B inhibitors (MAOBI), 
and catechol-O-methyl transferase inhibitors (COMTI)) using network meta-analy-
sis (NMA). MethOds: A systematic literature search was conducted in MEDLINE, 
MEDLINE In-Process, EMBASE, Cochrane Database of Systematic Reviews, Cochrane 
Central Register of Controlled Trials, DARE and HTA. A random effects NMA was used 
to determine the relative efficacy and safety of treatments on off-time reduction, 
three Unified Parkinson’s Disease Rating Scale (UPDRS) scores, patient withdrawals, 
and six adverse events in WinBUGS. An additional analysis was conducted to assess 
treatment class effects. Node-splitting approach was used to assess the assumption of 
consistency when direct and indirect evidence was combined. Results: Forty-three 
trials with 9,453 patients were identified. Immediate-release levodopa plus prami-
pexole produced the greatest reduction in off-time relative to immediate-release 
levodopa plus placebo (-1.71 hours a day; 95% CrI: -2.11, -1.35), followed by IPX066 
(-1.40; 95% CrI: -2.19, -0.67). The greatest improvement on UPDRS ADL score was given 
by add-on ropinirole (-2.33 points; 95% CrI: -3.53, -1.06); on UPDRS motor and total 
score was given by add-on pramipexole (-5.88 points; 95% CrI: -7.22, -4.63 and -10.09 
points; 95% CrI: -13.75, -6.56, respectively). Dyskinesia was increased with IPX066 and 
adjuvant therapy classes except for MAOBIs. Patient withdrawals were also increased 
with IPX066 and controlled-release levodopa. cOnclusiOns: The NMA showed that 
all treatments except controlled-release levodopa were associated with a statistically 
significant reduction in off-time. Dopamine agonist class as adjunctive to levodopa 
therapy had the greatest reduction. IPX066 was broadly comparable with add-on 
dopamine agonists on off-time reduction, and comparable with add-on MAOBIs and 
COMTIs on UPDRS scores. However, the treatments were associated with an increase 
in the risk of having dopaminergic side effects, particularly dyskinesia.
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Objectives: To describe caregivers’ Health Related Quality of Life (HRQoL), burden, 
anxiety and depression and their relation with patients’ symptoms in Parkinson 
disease (PD). MethOds: A descriptive, observational, longitudinal design in PD 
patients and their caregivers of ELEP study (2006-2010), in Spain. Information 
collected during 3 month per year for 4 years, included sociodemographic char-
acteristics, motor symptoms (SCOPA-Motor) and HRQoL (EQ-5D: index and VAS) 
from PD patients and burden (Zarit’s CBI), anxiety (HADS-A), depression (HADS-D) 
and HRQoL from their caregivers. Linear mixed models were performed to assess 
the relation between caregivers’ burden with the patients’ motor symptoms and 
HRQoL. Results: 174 PD patients, mean age: 63±11, 50% male, PD duration: 8±6 
years; 173 caregivers, 66.5% female, mean number of years taking care of patients: 
6±5, were included. Patients’ SCOPA-Motor varied from 39.3±8.4 in year 1 to 42.5±9.5 
in year 4; EQ-5D index and VAS from 0.7±0.3 and 63.7±20.3 to 0.6±0.3 and 60.3±17.9, 
respectively. Caregivers’ ZCBI varied from 17.6±12.6 to 20.0±14.8; EQ-5D index 
remained unchanged at 0.8±0.2, while VAS varied from 73.7±18.6 to 75.0±16.2; 
HADS-D scores changed between 4.0±3.7 and 4.4±4.3, and HADS-A from 6.7± 3.8 
to 6.9±4.3. Linear mixed models revealed that caregivers’ anxiety and depression 
negatively influenced their own perception of disease burden [HADS-A, Estimated 
coefficient (EC): 1.02 (SE: 0.15), p< 0.000; HADS-D, EC: 1.19 (SE: 0.17), p< 0.000]. Patients’ 
motor symptoms predicted worse caregiver burden [SCOPA-Motor EC: 0.22 (SE: 0.09), 
p= 0.014]. Decline in patients HRQoL implied a higher caregiver burden [EQ-5D index 
EC: -5.56 (SE: 2.70), p< 0.041]. cOnclusiOns: PD patients’ moderate motor symp-
toms and fair HRQoL worsened over time as did caregivers’ anxiety and disease 
automated Optical Character Recognition (OCR) system. Patients younger than 18 
years of age, diagnosed with Paget’s disease or purchasing pamidronic or zoledrnic 
acid due to cancer were excluded. Registry entry date was defined as the first medi-
cal event consistent with any of inclusion and all exclusion criteria. Results: We 
identified 118,141 patients with osteoporosis, with a point prevalence of 19% in 2013 
among members aged 50+, and an average incidence of approximately 6,300 cases 
a year. Average age at registry entry was 61 y/o for women and 66 y/o for men. 66% 
of the patients had more than one qualifying criteria. 28% of the registry patients 
were never treated. cOnclusiOns: The methods and results described may provide 
a model for the development of an important tool to assess the substantial burden 
of osteoporosis and to monitor the quality of care over time.
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Objectives: The use of PPIs to reduce the risk of upper GI events caused by 
NSAIDs is well documented. The aim of this study was to understand whether 
newly diagnosed patients with OA, RA or AS not previously exposed to PPIs, receive 
a gastro-protectant with their NSAID treatment at initiation or follow up in a 
primary care setting. MethOds: We analyzed data from primary care Electronic 
Medical Records in Ontario, Canada. Patients ≥ 18 years, who were new users of 
NSAIDs, NSAID plus a PPI, a fixed combination of diclofenac and misoprostol, or 
Celecoxib between January 1st 2010 and May 31st 2012 were selected. Patients must 
have had a diagnosis for OA, RA, or AS within 6 months of treatment initiation, 
but no diagnosis in the year prior. Patients were followed for 6 months to assess 
for subsequent PPI prescription. Patients prescribed a PPI in the last 12 months 
were excluded. Results were compared to Canadian longitudinal pharmacy 
data. Results: There were 692 patients included, 56% females and a mean age of 
44 years (SD 15). Naproxen was the most commonly used treatment (41%), followed 
by diclofenac (26%), celecoxib (14%) and diclofenac with misoprostol (19%). PPIs 
were added at treatment initiation in 2.5% of naproxen patients, 1.7% of diclofenac 
patients and 3.7% of patients with fixed combination of diclofenac and misopros-
tol. PPI prescription patterns within 6 months were similar and consistent with 
patterns observed in the Canadian longitudinal pharmacy data. cOnclusiOns: 
Results suggest that primary care physicians in Canada do not prescribe PPIs 
with NSAIDs at or within 6 months after NSAID initiation. Limitations include 
small sample size and young patient cohort. Further studies are required to bet-
ter understand the impact of low PPI concomitant use with NSAIDs, especially in 
older patients or those at a higher risk of GI events.
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Objectives: This study aimed to investigate and compare the gastrointestinal (GI) 
risk factors and treatment patterns of rheumatoid arthritis (RA) and osteoarthritis 
(OA) patients in real clinical practice of Korea. MethOds: This was a nationwide, 
cross-sectional study of patients taking non-steroidal anti-inflammatory drugs 
(NSAID, either non-selective or selective COX-2 inhibitor (COX2i)) from 20 hospitals 
between December 2012 and September 2013. Total 1,896 patients who were ≥ 20 
years old (RA: 981 OA: 915) and were taking NSAID at least 1 month were enrolled. 
Data were collected through medical chart review and patients survey. The GI risk 
factors included NSAID duration (≥ 3 months), high-dose of NSIAD use, drinking, 
smoking, comorbid disease, aspirin use, anticoagulant (warfarin) use, steroid use, 
Helicobacter pylori infection, experience of GI event (i. e. GI bleeding or ulcer). The 
treatment patterns were identified as non-selective NSAID (ns-NSAID) or COX2i 
with/without gastroprotective agents respectively. Results: In RA, proportion of 
patients taking NSAID≥ 3 months, smoker and steroid users were higher than in 
OA patients (p< . 0001). In OA, proportion of patients who have comorbid disease 
and take aspirin were higher than in RA patients (p< . 0001). The rest of the GI 
risk factors were present as a similar proportion in both groups. The percentage 
of treatment with COX2i (RA: 54.3% vs OA: 44.2%, p< . 001) and gastroprotective 
agents (RA: 83.0% vs OA: 78.3%, p= . 009) in RA patients was higher than that in 
OA patients. In older aged patients (age≥ 60) in both groups, there was tendency 
to get more treatment of COX2i (RA: 60.9%, OA: 50.2%) compared to ns-NSAID. 
Interestingly, as patients get more numbers of GI risk factors, there seemed to get 
more proportions of ns-NSAIDs users in both RA and OA patients. cOnclusiOns: 
The proportion of GI risk factors found in OA patients was comparable to that 
in RA patients. There was a tendency to show preferential ns-NSAID treatment 
pattern rather than COX2i especially in the presence of multiple GI risk factors 
in arthritis patients.
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AD dementia. The effectiveness of this test was evaluated for diagnostic accuracy. 
Diagnostic accuracy for identifying AD by ELISA was high (pooled sensitivity, 0.772 
(95% CI 0.747–0.796); pooled specificity, 0.732 (95% CI 0.699–0.762). cOnclusiOns: 
Reduced CSF Ab1–42 levels are of potential utility in the differential diagnosis of AD 
versus non-AD dementias and healthy controls.
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Objectives: Cystic fibrosis (CF) prevalence according to U. S. geographic region as 
well as patient age, gender and race was examined in the U. S. Medicaid population 
for patients younger than age 45. MethOds: Patients ≤ 45 years from the Medicaid 
fee-for-service (FFS) population (2008-2009) were identified using International 
Classification of Disease 9th Revision Clinical Modification (ICD-9-CM) diagnosis 
code 277.0x. Patients were required to have continuous Medicaid FFS enrollment 
in both years and no evidence of managed care enrollment. CF prevalence was 
stratified by U. S. region, state, age group, gender and race, and was measured by 
number and percentage of patients in each category. Results: A total of 2,142 
patients were diagnosed with CF among the Medicaid FFS population under age 45 
years in 2008 and 2009. Prevalence was the highest (0.17%) for patients under age 17 
years, followed by those age 18-35 (0.14%), and 36-45 years (0.06%). However, some 
states had the highest CF prevalence in the 18-35 age range (Colorado: 0.92%; North 
Dakota: 0.50%; Kentucky: 0.54%). CF prevalence by race was also examined with 
the following results: White (0.17%), Hispanic (0.10%), Asian (0.07%), Black (0.06%) 
and Native American (0.03%). Male patients had a relatively higher prevalence 
than female patients (0.14% vs. 0.12%). The highest CF prevalence was observed in 
Colorado (0.47%), followed by Maryland (0.46%), North Dakota (0.31%), Ohio (0.28%) 
and Pennsylvania (0.27%). Patients residing in the Midwest U. S. region had the 
highest prevalence rate (0.15%), compared to the South (0.15%), Northeast (0.12%) 
and West (0.04%) regions. cOnclusiOns: CF prevalence was the highest in patients 
age < 17 years nationwide, however, certain states showed the highest prevalence 
among patients age 18 to 35. White and male patients residing in the Midwest U. S. 
region were found to be at higher risk of a CF diagnosis.
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Objectives: To examine claims-based relapse rates and time to relapse among mul-
tiple sclerosis (MS) patients treated with natalizumab or propensity score matched 
patients treated with platform therapy (interferon beta/glatiramer acetate) in the 
US. MethOds: The Truven Health MarketScan Research Databases were used to 
identify adults with a MS (ICD-9-CM code 340) diagnosis treated with natalizumab 
or platform therapy; the first claim between January 1, 2009 and April 1, 2012 was the 
index. Patients had to have one year continuous enrollment pre- and post-index and 
remain on index therapy for 12 months. Patients were excluded if they used a non-
index therapy in the pre-index. Natalizumab and platform patients were propensity 
scored matched using nearest neighbor matching on demographic characteristics, 
selected comorbid conditions and medications, MS severity (using an adaptation 
of Kurtzke’s Functional System), pre-index relapse and pre-index expenditures. 
MS-relapse was defined as MS-related inpatient (IP) admission, IV or oral corticos-
teroid use. Cox Proportional Hazard models were used to evaluate time to relapse, 
controlling for demographic and pre-index clinical characteristics. Results: A total 
of 897 natalizumab patients met the study criteria, 882 of which were 1: 1 matched to 
882 platform therapy patients (mean age 45 years, 70% female) with a standardized 
difference < 10 on all matching measures. Compared to platform patients, natali-
zumab patients were significantly less likely to have MS-relapse post-index (26.5% 
vs. 35.5%, p< 0.001), with lower post-index rates of MS-related IP admissions (1.0% 
vs. 2.6%), IV-corticosteroid use (15.6% vs. 19.0%) and oral corticosteroid use (15.4% vs. 
23.1%) (all p< 0.001). Natalizumab patients also had 25 more relapse-free days (308 vs. 
283 days, p< 0.001). Post-index MS-relapse risk was lower for natalizumab patients 
(HR= 0.69, p< 0.001) after controlling for baseline characteristics. cOnclusiOns: 
Natalizumab was associated with a significantly lower risk and rate of MS-relapse 
and had longer time to a MS-relapse compared to platform therapy.
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bAckgROund: The most common surgical complication associated with shunt 
placement in Hydrocephalus patients is obstruction causing shunt malfunction. 
The primary cause of obstruction is incorrect placement of the catheter tip, most 
notably in the choroid plexus. Objectives: To investigate the clinical and eco-
nomic value of IGNS use in the accurate placement of catheters in Hydrocephalus 
patients. MethOds: A search of the Embase and PubMed electronic databases was 
conducted to identify studies evaluating the accuracy, effectiveness, quality-of-life 
(QOL) and economic aspects of IGNS in patients with Hydrocephalus. No language 
restrictions were applied. Results: We conducted a meta-analysis of studies report-
ing accuracy of ventricular catheter placement in patients with hydrocephalus 
undergoing shunt placement with stereotactic IGNS versus freehand technique. The 
definition of accurate catheter placement was similar in all studies. The meta-analysis 
showed the odds of achieving an accurate catheter placement for surgeons who utilize 
IGNS was almost 6 times higher (odds ratio 5.55, 95% CI [2.84, 10.85], P< 0.00001) than 
surgeons who used freehand placement techniques. Furthermore, accurate place-
burden. Improving the control of PD motor symptoms on patients may contribute 
to prevent anxiety and HRQoL deterioration in caregivers.
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Objectives: Gaucher disease (GD) is an inherited, rare, lysosomal storage disorder 
caused by a genetic deficiency of glucocerebrosidase. The result is the accumulation 
of the substrate, glucosylceramide, in the lysosomes of macrophage cells in the liver, 
spleen, bones, lungs, and other vital tissues. Three subtypes of Gaucher disease are 
recognized: type 1 (GD1, non-neuropathic), type 2 (GD2, acute neuropathic), and type 
3 (GD3, subacute/chronic neuropathic). Clinical manifestations of the disease are mul-
tisystemic, clinically heterogeneous and require lifelong management. MethOds: 
To better understand the burden of GD, a comprehensive review of the published 
literature was conducted. MEDLINE, EMBASE, CENTRAL and “grey” literature sources 
published in English between January 1990 and February 2013 were searched for rel-
evant publications. Results: A total of 97 publications focusing on the epidemiologic, 
clinical, and socioeconomic burden of GD, treatment options and guidelines were 
summarized. The standardized incidence and prevalence of GD in the general popu-
lation varies from 0.30 to 5.80 per 100,000 and 0.33 to 1.75 per 100,000, respectively, 
and GD1 is the predominant type in most regions. The risk of mortality is highest in 
GD patients younger than age 5 years and generally increased after age 55; the life 
expectancy is lower than the general population. Common manifestations of GD such 
as anemia, thrombocytopenia, splenomegaly, hepatomegaly and bone disease lead 
to a decreased quality of life. Reported GD comorbidities include Parkinson’s disease 
and cancer. Current treatment options consist of enzyme replacement therapy (ERT, 
standard of care) and substrate reduction therapy (SRT). ERT is the standard of care, 
though unmet needs still exist, especially for GD2 and GD3. cOnclusiOns: GD is a 
rare, chronic disease associated with significant burden to patients and caregivers. 
While ERT is an effective and well-established treatment for GD patients, several 
unmet needs exist and further research is needed in this area.
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Objectives: Restless leg syndrome (RLS) is a condition with possibly high prevalence 
in hemodialysis (6-60% according to the literature), and a specific treatment available. 
Thus it’s important to identify it among other conditions present in this population 
that might confound diagnosis (such as peripheral vascular disease or neuropathies). 
An approach based on a self-completed screening test will be assessed in this study, 
along with an estimation of RLS prevalence in hemodialysis. MethOds: Patients 
from two hemodialysis units answered a RLS screening test. Those with a positive 
screening completed the International Restless Legs Syndrome Study Group Rating 
Scale (IRLS) that assesses symptom severity. A neurophysiologist performed a clini-
cal interview to confirm the diagnosis, including a supervised administration of the 
IRLS. Results: 164 patients were recruited. Mean age was 65.7 years (range 33-87; 
Pct25-75: 55.5-77.5), 67% were male and mean time in dialysis was 64.16 months. 
Self-completed screening test identified 69 possible cases of RLS (42.07%). 44 (26.8%) 
patients had RLS symptoms according to the self-completed IRLS, and 79% of them 
were classified as having moderate to severe RLS symptoms. The clinician confirmed 
just 22 of those cases (13.4% of the total sample), with a demographic profile similar 
to the sample. The screening test had in this sample a sensitivity of 100%, specificity 
66.43% and positive predictive value 31.88%. cOnclusiOns: This study found RLS is 
a relatively common condition in hemodialysis patients. The screening test showed 
a high sensitivity to detect RLS, but very low specificity, so the confirmation of an 
expert neurologist or neurophysiologist is neccesary.
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Objectives: The purpose of this study was to carry out systematic review of the 
literature and meta-analysis to evaluate the diagnostic utility of cerebrospinal fluid 
(CSF) levels of the 42 amino acid form of amyloid-b (Ab1−42) as a biomarker for dif-
ferentiating Alzheimer’s disease (AD) from non-AD dementia. MethOds: Design - 
Systematic literature review was used to evaluate the effectiveness of the Ab for the 
diagnosis of Alzheimer’s disease. The Scottish Intercollegiate Guidelines Network 
(SIGN) tool was used by two evaluators to evaluate independently the quality of the 
15 studies. Data sources - The literature review covered from October 27, 1946, to 
October 22, 2013, and searched eight domestic databases including Korea Med and 
international databases including Ovid-MEDLINE, EMBASE, and Cochrane Library. 
Eligibility criteria for selecting studies - Primary criteria for inclusion were valid 
studies on (i) patients with mild cognitive impairment with confirmed or suspected 
AD and non-AD dementia, and (ii) assessment of Ab1−42levels using appropriate 
comparative tests. Results: A total of 15 studies (15 diagnostic evaluation stud-
ies) were identified in which levels of CSF Ab1−42 were assessed. Meta-analysis 
was performed on nine robust studies that compared confirmed AD with healthy 
individuals (n = 1587), 10 studies that compared AD with non-AD dementias (n = 
860), and four studies that compared a-MCI (amnestic mild cognitive impairment) 
with na-MCI (non-amnestic mild cognitive impairment) subjects (n = 857). Overall, 
Ab1–42levels were reduced in CSF from AD patients versus healthy controls or non-
